ConductScience.org, home

Paper36951997

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.

Kayki-Mutlu G and 3 others. Naunyn Schmiedebergs Arch Pharmacol, 2023. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Papers, record 36951997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36951997

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.9
iCite
Revised in PubMed
2023-10-16
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kayki-Mutlu GGizem
2Aksoyalp ZSZinnet Sevval
3Wojnowski LLeszek
4Michel MCMartin C

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
Biological ProductsMajor topic
United States
Humans
United States Food and Drug Administration
Pandemics
Pharmaceutical Preparations
Drug Approval

Source PubMed

Download CSV of topics

References98

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125904506IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.Mol Cancer Ther2015https://conductscience.org/library/papers/25904506PubMed
234495425Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.Jpn J Ophthalmol2021https://conductscience.org/library/papers/34495425PubMed
334529832THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.Br J Pharmacol2021https://conductscience.org/library/papers/34529832PubMed
435417638Mitapivat versus Placebo for Pyruvate Kinase Deficiency.N Engl J Med2022https://conductscience.org/library/papers/35417638PubMed
535652823Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.Amyloid2022https://conductscience.org/library/papers/35652823PubMed
635820547
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol2023https://conductscience.org/library/papers/35820547PubMed
735736599New Drug for Metastatic Castration-Resistant Prostate Cancer.Am J Nurs2022https://conductscience.org/library/papers/35736599PubMed
834936739Trial of Spesolimab for Generalized Pustular Psoriasis.N Engl J Med2021https://conductscience.org/library/papers/34936739PubMed
935946351Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?Immunotherapy2022https://conductscience.org/library/papers/35946351PubMed
1031791824
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
J Am Acad Dermatol2020https://conductscience.org/library/papers/31791824PubMed
1133761207Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.N Engl J Med2021https://conductscience.org/library/papers/33761207PubMed
1236418672Spesolimab: First Approval.Drugs2022https://conductscience.org/library/papers/36418672PubMed
1335785754Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.Cancer Treat Rev2022https://conductscience.org/library/papers/35785754PubMed
1432818963A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis.Clin Infect Dis2021https://conductscience.org/library/papers/32818963PubMed
1536387582A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.Lung Cancer (Auckl)2022https://conductscience.org/library/papers/36387582PubMed
1635803286Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.Lancet Oncol2022https://conductscience.org/library/papers/35803286PubMed
1731609882DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).Plast Reconstr Surg2020https://conductscience.org/library/papers/31609882PubMed
1835679950Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.Gastroenterology2022https://conductscience.org/library/papers/35679950PubMed
1932687266
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cancer Med2020https://conductscience.org/library/papers/32687266PubMed
2027042127Tremelimumab: research and clinical development.Onco Targets Ther2016https://conductscience.org/library/papers/27042127PubMed

See all 98 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
41807809A year in pharmacology: new drugs approved by the US food and drug administration in 2025.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41807809PubMed
41196339Do GPCRs constitute the target of 30% of newly approved drugs in Germany?Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41196339PubMed
40608116Comparison of drug approvals of the FDA and EMA between 2013 and 2023.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/40608116PubMed
40163152A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40163152PubMed
39177747The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model.Handb Exp Pharmacol2024https://conductscience.org/library/papers/39177747PubMed
38530400A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.Naunyn Schmiedebergs Arch Pharmacol2024https://conductscience.org/library/papers/38530400PubMed
38371570Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage.Indian J Dermatol2023https://conductscience.org/library/papers/38371570PubMed

Download CSV of cited by

Genes31

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AHR196PubTator's text mininghttps://conductscience.org/library/genes/196NCBI Gene
ANGPT2285PubTator's text mininghttps://conductscience.org/library/genes/285NCBI Gene
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene
AVP551PubTator's text mininghttps://conductscience.org/library/genes/551NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CDKL56792PubTator's text mininghttps://conductscience.org/library/genes/6792NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CYP2C191557PubTator's text mininghttps://conductscience.org/library/genes/1557NCBI Gene
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
CYP51A11595PubTator's text mininghttps://conductscience.org/library/genes/1595NCBI Gene
FOLH12346PubTator's text mininghttps://conductscience.org/library/genes/2346NCBI Gene
FOLR12348PubTator's text mininghttps://conductscience.org/library/genes/2348NCBI Gene
GIP2695PubTator's text mininghttps://conductscience.org/library/genes/2695NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
IL33562PubTator's text mininghttps://conductscience.org/library/genes/3562NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene

See all 31 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36951997

GET https://conductscience.org/api/papers/v1/36951997/references?page=2